Cost Of Failure Following Reimplantation After a 2-Stage Exchange Strategy For Hip Or Knee Prosthetic Joint Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03612076|
Recruitment Status : Completed
First Posted : August 2, 2018
Last Update Posted : August 8, 2018
This study concerns patients having had an infection on their prosthesis (hip, knee,..) and for whom a 2-step exchange of prosthesis has been done.
A 2-step exchange consists in explantation of the prosthesis and implementation of a spacer at the first stage, and reimplantation of a new prosthesis in a second stage. Patients with late prosthetic joint infection are at risk for superinfection at the time of reimplantation.
The aim of this study is to determine the global cost of management of prosthetic joint infection.
|Condition or disease||Intervention/treatment|
|Prosthetic Joint Infection||Other: Global cost of management of PJI|
|Study Type :||Observational|
|Actual Enrollment :||115 participants|
|Official Title:||Cost of Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection|
|Actual Study Start Date :||December 1, 2016|
|Actual Primary Completion Date :||July 1, 2018|
|Actual Study Completion Date :||July 1, 2018|
|Global cost of management of PJI||
Other: Global cost of management of PJI
estimation of the global cost to manage PJI with 2-step exchange over 3 years
- Global cost of management of PJI [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) ]The following data are collected : duration of hospitalization at the Croix Rousse hospital (surgery unit, department of infectiology, other…) and in post-acute care structures, bacteriology, surgeries, medical treatments… and all acts realized throughout the management of the PJI.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03612076
|Hospices Civils de Lyon|
|Lyon, France, 69004|
|Principal Investigator:||Tristan Ferry, Md,PhD||Hospices Civils de Lyon - Hôpital de la Croix-Rousse|